Hybrid-cell vaccines for cancer immune therapy.
Hybrid cells generated by fusing allogenic-presenting cells, such as dendritic cells, with tumor cells are a new tool in cancer immunotherapy which are designed to enhance the immunogenicity of antigenic tumors by presenting the whole spectrum of tumor-associated antigens, by providing the co-stimulatory molecules required for T-cell activation, and by the expression of allogenic MHC molecules for recruitment and activation of T-cell help. This approach has been successfully tested in animal models as well as in clinical phaseI/II trials with various tumors. Besides clinical repsonses, induction of tumor-specific cytolytic Tcells were observed. The electrofusion protocol described here has the advantage of high fusion efficiency, high hybrid-cell viability, as well as high reproducibility, and can be used for various tumor cell types after minor adjustments are made to the instrument settings in order to process large numbers of dendritic cells with consistent efficiencies.
D001402:B-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D002459:Cell Fusion / Q000379:methods; D003713:Dendritic Cells / Q000276:immunology; D005434:Flow Cytometry; D006801:Humans; D006822:Hybrid Cells / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods*; D008856:Microscopy, Fluorescence; D015166:Monitoring, Immunologic; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D018579:Patient Selection; D013194:Staining and Labeling; D014407:Tumor Cells, Cultured / Q000276:immunology; D019139:Tumor Escape / Q000276:immunology; D014611:Vaccination / Q000379:methods
D019496:Cancer Vaccines